Compare Fresenius Kabi Onco. with Biocon Ltd - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

FRESENIUS KABI ONCO. vs BIOCON - Comparison Results

FRESENIUS KABI ONCO.     Change

Fresenius Kabi Oncology is the erstwhile Dabur Pharma, which was incorporated in March 2003. The company is a leading player in oncology in India and the international markets. Fresenius Kabi Oncology operates in the regulated markets namely the US a... More

BIOCON  
   Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    FRESENIUS KABI ONCO. BIOCON FRESENIUS KABI ONCO./
BIOCON
 
P/E (TTM) x 22.1 19.4 113.9% View Chart
P/BV x 3.1 3.0 103.6% View Chart
Dividend Yield % 0.0 0.4 -  

Financials

 FRESENIUS KABI ONCO.   BIOCON
EQUITY SHARE DATA
    FRESENIUS KABI ONCO.
Mar-13
BIOCON
Mar-18
FRESENIUS KABI ONCO./
BIOCON
5-Yr Chart
Click to enlarge
High Rs1761,188 14.8%   
Low Rs79305 25.7%   
Sales per share (Unadj.) Rs37.768.7 54.8%  
Earnings per share (Unadj.) Rs5.17.6 67.4%  
Cash flow per share (Unadj.) Rs6.714.0 48.1%  
Dividends per share (Unadj.) Rs01.00 0.0%  
Dividend yield (eoy) %00.1 0.0%  
Book value per share (Unadj.) Rs42.586.3 49.3%  
Shares outstanding (eoy) m158.23600.00 26.4%   
Bonus/Rights/Conversions -IS-  
Price / Sales ratio x3.410.9 31.1%   
Avg P/E ratio x25.098.9 25.3%  
P/CF ratio (eoy) x18.953.4 35.4%  
Price / Book Value ratio x3.08.6 34.6%  
Dividend payout %013.2 0.0%   
Avg Mkt Cap Rs m20,135447,900 4.5%   
No. of employees `0001.26.1 18.7%   
Total wages/salary Rs m7039,311 7.6%   
Avg. sales/employee Rs Th5,176.26,705.8 77.2%   
Avg. wages/employee Rs Th610.41,514.2 40.3%   
Avg. net profit/employee Rs Th699.6736.9 94.9%   
INCOME DATA
Net Sales Rs m5,96341,234 14.5%  
Other income Rs m182,062 0.9%   
Total revenues Rs m5,98143,296 13.8%   
Gross profit Rs m1,4308,291 17.2%  
Depreciation Rs m2583,851 6.7%   
Interest Rs m-26615 -4.2%   
Profit before tax Rs m1,2165,887 20.7%   
Minority Interest Rs m0213 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-680-   
Tax Rs m3421,569 21.8%   
Profit after tax Rs m8064,531 17.8%  
Gross profit margin %24.020.1 119.3%  
Effective tax rate %28.126.7 105.6%   
Net profit margin %13.511.0 123.0%  
BALANCE SHEET DATA
Current assets Rs m5,10241,486 12.3%   
Current liabilities Rs m2,38521,413 11.1%   
Net working cap to sales %45.648.7 93.6%  
Current ratio x2.11.9 110.4%  
Inventory Days Days15064 234.6%  
Debtors Days Days11394 120.3%  
Net fixed assets Rs m5,14850,661 10.2%   
Share capital Rs m1583,000 5.3%   
"Free" reserves Rs m6,55648,808 13.4%   
Net worth Rs m6,73251,808 13.0%   
Long term debt Rs m95217,898 5.3%   
Total assets Rs m10,38899,897 10.4%  
Interest coverage x-45.810.6 -433.0%   
Debt to equity ratio x0.10.3 40.9%  
Sales to assets ratio x0.60.4 139.1%   
Return on assets %7.55.2 145.7%  
Return on equity %12.08.7 136.9%  
Return on capital %14.69.6 151.6%  
Exports to sales %74.50-   
Imports to sales %24.80-   
Exports (fob) Rs m4,441NA-   
Imports (cif) Rs m1,477NA-   
Fx inflow Rs m5,29812,058 43.9%   
Fx outflow Rs m1,7727,348 24.1%   
Net fx Rs m3,5254,710 74.8%   
CASH FLOW
From Operations Rs m1,2746,621 19.2%  
From Investments Rs m-1,204-6,840 17.6%  
From Financial Activity Rs m-196-2,397 8.2%  
Net Cashflow Rs m-126-2,612 4.8%  

Share Holding

Indian Promoters % 0.0 40.4 -  
Foreign collaborators % 81.0 20.6 393.2%  
Indian inst/Mut Fund % 0.3 8.4 3.6%  
FIIs % 9.6 10.7 89.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 9.1 19.9 45.7%  
Shareholders   42,599 109,995 38.7%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare FRESENIUS KABI ONCO. With:   WYETH LTD  PIRAMAL ENTERPRISES  JUBILANT LIFE SCIENCES  SUN PHARMA  PFIZER  

Compare FRESENIUS KABI ONCO. With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Indian Stock Markets Remain in Green This Week: Is the Rebound Here?(Podcast)

After a long period of underperformance, stock markets traded in green territory throughout the week. So, is this is a trend reversal and is the bottom forming in the market?

Related Views on News

BIOCON Announces Quarterly Results (1QFY20); Net Profit Down 11.5% (Quarterly Result Update)

Jul 29, 2019 | Updated on Jul 29, 2019

For the quarter ended June 2019, BIOCON has posted a net profit of Rs 1 bn (down 11.5% YoY). Sales on the other hand came in at Rs 5 bn (down 57.2% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

BIOCON Announces Quarterly Results (4QFY19); Net Profit Down 53.8% (Quarterly Result Update)

Apr 26, 2019 | Updated on Apr 26, 2019

For the quarter ended March 2019, BIOCON has posted a net profit of Rs 705 m (down 53.8% YoY). Sales on the other hand came in at Rs 8 bn (down 34.7% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

BIOCON LTD Announces Quarterly Results (3QFY19); Net Profit Up 169.2% (Quarterly Result Update)

Jan 28, 2019 | Updated on Jan 28, 2019

For the quarter ended December 2018, BIOCON LTD has posted a net profit of Rs 2 bn (up 169.2% YoY). Sales on the other hand came in at Rs 15 bn (up 45.6% YoY). Read on for a complete analysis of BIOCON LTD's quarterly results.

BIOCON LTD Announces Quarterly Results (2QFY19); Net Profit Up 501.9% (Quarterly Result Update)

Nov 9, 2018 | Updated on Nov 9, 2018

For the quarter ended September 2018, BIOCON LTD has posted a net profit of Rs 4 bn (up 501.9% YoY). Sales on the other hand came in at Rs 13 bn (up 36.4% YoY). Read on for a complete analysis of BIOCON LTD's quarterly results.

BIOCON LTD Announces Quarterly Results (1QFY19); Net Profit Up 47.2% (Quarterly Result Update)

Jul 30, 2018 | Updated on Jul 30, 2018

For the quarter ended June 2018, BIOCON LTD has posted a net profit of Rs 1 bn (up 47.2% YoY). Sales on the other hand came in at Rs 11 bn (up 20.4% YoY). Read on for a complete analysis of BIOCON LTD's quarterly results.

More Views on News

Most Popular

My 3 Best Small-cap Stocks to Get Rich in this Market Rebound(Profit Hunter)

Oct 14, 2019

This is once in a decade opportunity to make a killing from smallcap rebound.

Finally, Is the Share Price of Yes Bank Ready for a Rebound?(The 5 Minute Wrapup)

Oct 7, 2019

Here's what every individual investor must know about Yes Bank...

Two Stocks to Buy in the Great Indian Festival(Profit Hunter)

Oct 11, 2019

Discounts are not just limited to E-tailers. You can buy stocks at 50% off too. Here are two stocks to buy now.

Buy these 3 Stocks for Rebound Riches

Oct 18, 2019

Equitymaster's smallcap guru and editor of Hidden Treasure, Richa Agarwal, talks to us about the rebound in the stock market, and the best stocks to profit from it. Listen in...

The One Stock I Like in this Market(The 5 Minute Wrapup)

Oct 10, 2019

There are rare periods in markets when you get good quality stocks at attractive valuations. Is this one such period?

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

FRESENIUS KABI ONCO. SHARE PRICE


Jan 2, 2014 (Close)

TRACK FRESENIUS KABI ONCO.

  • Track your investment in FRESENIUS KABI ONCO. with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON FRESENIUS KABI ONCO.

FRESENIUS KABI ONCO. 8-QTR ANALYSIS

COMPARE FRESENIUS KABI ONCO. WITH

MARKET STATS